Safety and tolerability of testosterone patch therapy for up to 4 years in surgically menopausal women receiving oral or transdermal oestrogen

Gynecological Endocrinology

Volumn 27, Issue 1, 2011, Pages 39-48

  Nachtigall, Lila ^a   Casson, Peter ^b   Lucas, Johna ^c   Schofield, Victoria ^d   Melson, Chad ^c   Simon, James A ^e  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b FLETCHER ALLEN HEALTH CARE   (United States)

^c Warner Chilcott   (United States)

^d PROCTER AND GAMBLE COMPANY   (United States)

^e GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

Androgen replacement therapy; androgens; menopause

Indexed keywords

CONJUGATED ESTROGEN; ESTROGEN; PLACEBO; TESTOSTERONE;

ACNE; ADULT; AGED; AGGRESSION; ALOPECIA; ANDROGEN THERAPY; ANGINA PECTORIS; ANXIETY; APPLICATION SITE REACTION; ARTICLE; BRAIN ISCHEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EXPOSURE; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ESTROGEN THERAPY; FEMALE; HAIR GROWTH; HEART INFARCTION; HEART PALPITATION; HUMAN; HYPOACTIVE SEXUAL DESIRE DISORDER; HYSTERECTOMY; LONG TERM CARE; MAJOR CLINICAL STUDY; MENOPAUSE; MIGRAINE; PRIORITY JOURNAL; SALPINGOOOPHORECTOMY; SEXUAL DYSFUNCTION; SIDE EFFECT; TRANSDERMAL PATCH; VOICE DEEPENING;

ADMINISTRATION, CUTANEOUS; ADULT; AGED; BREAST NEOPLASMS; CLITORIS; DOUBLE-BLIND METHOD; ESTROGENS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; HYSTERECTOMY; MENOPAUSE, PREMATURE; MIDDLE AGED; OVARIECTOMY; PLACEBOS; SALPINGECTOMY; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL; STROKE; TESTOSTERONE; VULVAR DISEASES;

EID: 78650154369     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513590.2010.487597     Document Type: Article

References (43)

1. Shifren JL, Braunstein GD, Simon JA, Casson PR, Buster JE, Redmond GP, Burki RE, Ginsburg ES, Rosen RC, Leiblum SR, et al. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med 2000;343:682-688.
2. Goldstat R, Briganti E, Tran J, Wolfe R, Davis SR. Transdermal testosterone therapy improves well-being, mood, and sexual function in premenopausal women. Menopause 2003;10:390-398.
3. Ling S, Komesaroff PA, Sudhir K. Cardiovascular physiology of androgens and androgen testosterone therapy in postmenopausal women. Endocr Metab Immune Disord Drug Targets 2009;9:29-37.
4. Watts NB, Notelovitz M, Timmons MC, Addison WA, Wiita B, Downey LJ. Comparison of oral estrogens and estrogens plus androgen on bone mineral density, menopausal symptoms, and lipid-lipoprotein profiles in surgical menopause. Obstet Gynecol 1995;85:529-537.
5. Davis SR, McCloud P, Strauss BJ, Burger H. Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality. Maturitas 1994;21:227-236.
6. Simon J, Braunstein G, Nachtigall L, Utian W, Katz M, Miller S, Waldbaum A, Bouchard C, Derzko C, Buch A. Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder. J Clin Endocrinol Metab 2005;90:5226-5233. (Pubitemid 41262278)
7. Buster JE, Kingsberg SA, Aguirre O, Brown C, Breaux JG, Buch A, RodenbergCA, WekselmanK, Casson P. Testosterone patch for low sexual desire in surgically menopausal women: A randomized trial. Obstet Gynecol 2005;105:944-952. (Pubitemid 40571010)
8. Shifren JL, Braunstein GD, Simon JA, Casson PR, Buster JE, Redmond GP, Burki RE, Ginsburg ES, Rosen RC, Leiblum SR. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med 2000;343:682-688.
9. Braunstein GD, Sundwall DA, Katz M, Shifren JL, Buster JE, Simon JA, Bachman G, Aguirre O, Lucas JD, Rodenberg CA. Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: A randomized, placebo-controlled trial. Arch Intern Med 2005;165:1582-1589. (Pubitemid 41124151)
10. Davis SR, van der Mooren MJ, van Lunsen RH, Lopes P, Ribot C, Rees M, Moufarege A, Rodenberg C, Buch A, Purdie PW. Efficacy and safety of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: A randomized, placebo-controlled trial. Menopause 2006;13:387-396.
11. Shifren JL, Davis SR, Moreau M, Waldbaum A, Bouchard C, Derogatis L, Derzko C, Bearnson P, Kakos N, O'Neill S. Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally menopausal women: Results from the Intimate NM1 study. Menopause 2006;143:770-779.
12. Lorenzo EM. Familial study of hirsutism. J Clin Endocrinol 1970;31:556-564.
13. Palatsi R, Hirvensalo E, Liukko P, Malmiharju T, Mattila L, Riihiluoma P, Ylöstalo P. Serum total and unbound testosterone and sex hormone binding globulin (SHBG) in female acne patients treatment with two different oral contraceptives. Acta Derm Vernereol (Stockh) 1984;64:517-523. (Pubitemid 15223205)
14. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Prinicpal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333. (Pubitemid 34761611)
15. http://seer.cancer.gov, Age-Specific SEER Incidence Rates, 2002-2006; Access Date: 09OCT2009
16. Spratt JS, Meyer JS, Spratt JA. Rates of growth of human solid neoplasms: Part I. J Surg Oncol 1995;60,137-146.
17. Tamimi RM, Hankinson SE, Chen WY, Rosner B, Colditz GA. Combined estrogen and testosterone use and risk of breast cancer in postmenopausal women. Arch Intern Med 2006;166:1483-1489. (Pubitemid 44125867)
18. Brinton LA, Hoover R, Fraumeni JF Jr. Menopausal oestrogens and breast cancer risk: An expanded case-control study. Br J Cancer 1986;54:825-832. (Pubitemid 17177542)
19. Ewertz M. Influence of non-contraceptive exogenous and endogenous sex hormones on breast cancer risk in Denmark. Int J Cancer 1988;42:832-838. (Pubitemid 19012909)
20. Dimitrakakis C, Jones RA, Liu A, Bondy CA. Breast cancer incidence in postmenopausal women using testosterone in addition to usual hormone therapy. Menopause 2004;11:531-535. (Pubitemid 40362151)
21. Colditz GA, Hankinson SE, Hunter DJ, Willett WC, Manson JE, Stampfer MJ, Hennekens C, Rosner B, Speizer FE. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995;332: 1589-1593.
22. Berrino F, Muti P, Micheli A, Bolelli G, Krogh V, Sciajno R, Pisani P, Panico S, Secreto G. Serum sex hormone levels after menopause and subsequent breast cancer. J Natl Cancer Inst 1996;88:291-296. (Pubitemid 26073374)
23. Dorgan JF, Longcope C, Stephenson HE Jr, Falk RT, Miller R, Franz C, Kahle L, Campbell WS, Tangrea JA, Schatzkin A. Relation of prediagnostic serum estrogen and androgen levels to breast cancer risk. Cancer Epidemiol Biomarkers Prev 1996;5:533-539. (Pubitemid 26235020)
24. Key T, Appleby P, Barnes I, Reeves G. Endogenous Hormones and Breast Cancer Collaborative Group. Endogenous sex hormones and breast cancer in postmenopausal women: Reanalysis of nine prospective studies. J Natl Cancer Inst 2002;94:606-616. (Pubitemid 34498648)
25. Cauley JA, Lucas FL, Kuller LH, Stone K, Browner W, Cummings SR. Elevated serum estradiol and testosterone concentrations are associated with a high risk for breast cancer. Study of Osteoprotic Fractures Research Group. Ann Intern Med 1999;130:270-277. (Pubitemid 29091854)
26. Hankinson SE, Willett WC, Manson JE, Colditz GA, Hunter DJ, Spiegelman D, Barbieri RL, Speizer FE. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 1998;90:1292-1299. (Pubitemid 28433474)
27. Zeleniuch-Jacquotte A, Bruning PF, Bonfrer JM, Koenig KL, Shore RE, Kim MY, Pasternack BS, Toniolo P. Relation of serum levels of testosterone and dehydroepiandrosterone sulfate to risk of breast cancer in postmenopausal women. Am J Epidemiol 1997;145:1030-1038. (Pubitemid 27215486)
28. Thomas HV, Key TJ, Allen DS, Moore JW, Dowsett M, Fentiman IS, Wang DY. A prospective study of endogenous serum hormone concentrations and breast cancer risk in postmenopausal women on the island of Guernsey. Br J Cancer 1997;76:401-405. (Pubitemid 27308094)
29. Lipworth L, Adami HO, Trichopoulos D, Carlström K, Mantzoros C. Serum steroid hormone levels, sex hormonebinding globulin, and body mass index in the etiology of postmenopausal breast cancer. Epidemiology 1996;7: 96-100. (Pubitemid 26003853)
30. Ando S, De Amicis F, Rago V, Carpino A, Maggiolini M, Panno ML, Lanzino M. Breast cancer: From estrogen to androgen receptor. Mol Cell Endocrinol 2002;193:121-128. (Pubitemid 34823616)
31. Ortmann J, Prifti S, Bohlmann MK, Rehberger-Schneider S, Strowitzki T, Rabe T. Testosterone and 5 alpha-dihydrotestosterone inhibit in vitro growth of human breast cancer cell lines. Gynecol Endocrinol 2002;16:113-120. (Pubitemid 34496877)
32. Dimitrakakis C, Zhou J, Want J, Belanger A, LaBrie F, Cheng C, et al. A physiologic role for testosterone in limiting estrgenic stimulation of the breast. Menopause 2003;10: 292-298. (Pubitemid 36870501)
33. Zhou J, Ng S, Adesanya-Famuiya O, Anderson K, Bondy CA. Testosterone inhibits estrogen-induced mammary epithelial proliferation and suppresses estrogen receptor expression. FASEB J 2000;14:1725-1730.
34. Hofling M, Hirschberg A, Skoog L, Tani E, Hagerstrom T, von Schoultz B. Testosterone inhibits estrogen/progestogeninduced breast cell proliferation in postmenopausal women. Menopause 2007;14:183-190. (Pubitemid 46673468)
35. Landahl S, Bengtsson C, Sigurdsson J, Svanborg A, Svardsudd S. Age-related changes in blood pressure. Hypertension 1986;8:1044-1049. (Pubitemid 17176795)
36. Kuczmarski RJ, Flegal KM, Campbell SM, Johnson CL. Increasing prevalence of overweight among US adults: The National Health and Nutrition Examination survey 1960- 1991. JAMA 1994;272:205-211. (Pubitemid 24209082)
37. U.S. Department of Health and Human Services. The seventh report of the joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.
38. Reeves KW, Stone RA, Modugno F, Ness RB, Vogel VG, Weissfeld JL, Habel LA, Sternfeld B, Cauley JA. Longitudinal association of anthropometry with mammographic breast density in the Study of Women's Health Across the Nation. Int J Cancer 2009;124:1169-1177.
39. Basaria S, Dobbs AS. Safety and adverse effects of androgens: How to counsel patients. Mayo Clin Proc 2004;79(4 Suppl): S25-S32. (Pubitemid 38401762)
40. Liu PY, Death AK, Handelsman DJ. Androgens and cardiovascular disease. Endocr Rev 2003;24:313-340. (Pubitemid 36724373)
41. Wu FC, von Eckardstein A. Androgens and coronary artery disease. Endocr Rev 2003;24:183-217. (Pubitemid 36515284)
42. Rexrode KM, Manson JE, Lee I-M, Ridker PM, Sluss PM, Cook NR, Buring JE. Sex Hormone levels and risk of cardiovascular events in postmenopausal women. Circulation 2003;108:1688-1693. (Pubitemid 37243655)
43. Laughlin GA, Goodell V, Barrett-Connor E. Extremes of endogenous testosterone are associated with increased risk of incident coronary events in older women. J Clin Endocrinol Metab 2010;95:740-747.